MedTrace Logo

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

NCT07029139 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2025-06-19

No results posted yet for this study

Summary

This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants with primary membranous nephropathy.

The study has two parts. Part one is dose escalation part, and Part two is dose expansion part.

Conditions

Interventions

DRUG

JMT601 Injection

In accordance with the protocol

DRUG

Rituximab

In accordance with the protocol

DRUG

Cyclosporin Capsules

In accordance with the protocol

Sponsors & Collaborators

  • Shanghai JMT-Bio Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2027-04-01
Completion
2029-03-01

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07029139 on ClinicalTrials.gov